Physician profile
Robert E Kell
NPI 1710086236
$1,203.15
in general payments reported to CMS, 2019-2025
23 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $90.98 · 2021: $125 · 2022: $44.94 · 2023: $262 · 2024: $351 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $294.28 | 2019-2025 | |
| Amgen INC. | $139.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $131.84 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $108.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $76.07 | 2023-2025 | Veozah |
| Roche Diagnostics Corporation | $72.30 | 2019-2020 | |
| Pfizer INC. | $70.89 | 2019-2025 | |
| Exeltis, USA INC. | $34.56 | 2024 | Slynd |
| Lilly USA, LLC | $31.98 | 2019-2024 | Zepbound |
| Glaxosmithkline, LLC. | $30.09 | 2023-2024 | Trelegy Ellipta |
| Organon LLC | $28.40 | 2024-2025 | Nexplanon |
| Therapeuticsmd, INC. | $17.77 | 2020 | |
| Almatica Pharma LLC | $17.59 | 2023 | Sertraline Hcl, Loreev Xr |
| Kowa Pharmaceuticals America, INC. | $17.15 | 2023 | Seglentis |
| Intra-Sana Laboratories | $17.13 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.43 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.19 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.45 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.15 | 2021 | |
| Zyla Life Sciences, INC. | $14.05 | 2019 | |
| Daiichi Sankyo INC. | $13.97 | 2020 | |
| Avion Pharmaceuticals | $12.69 | 2021 | |
| Currax Pharmaceuticals LLC | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.